Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.34 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.34 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.34 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.34 |
| ▸ | CYP46A1 | Q9Y6A2 | 5/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703087 | 1.00 | AR (0.47) | ARFFAR1FFAR4DDR1PGR | |
| SCHEMBL524308 | 0.92 | AR (0.50) | ARFFAR1FFAR4PGRCYP46A1 | |
| SCHEMBL30436667 | 0.92 | AR (0.50) | ARFFAR1FFAR4PGRCYP46A1 | |
| SCHEMBL524307 | 0.92 | AR (0.50) | ARFFAR1FFAR4PGRCYP46A1 | |
| SCHEMBL1703045 | 0.87 | AR (0.42) | ARFFAR4NR3C1SMN1; SMN2HSD11B1 | |
| SCHEMBL1703049 | 0.87 | AR (0.42) | ARFFAR4NR3C1SMN1; SMN2HSD11B1 | |
| SCHEMBL1702843 | 0.84 | AR (0.40) | ARFFAR4PGR | |
| SCHEMBL12469677 | 0.79 | SMN1; SMN2 (0.54) | ARFFAR4SMN1; SMN2 | |
| SCHEMBL14525275 | 0.79 | AR (0.56) | ARPGRCYP46A1NR1I2NR3C1 | |
| SCHEMBL15168736 | 0.79 | SMN1; SMN2 (0.54) | ARFFAR4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627627-B1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-2627643-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | BRISTOL MYERS SQUIBB CO (US) | 2016-11-23 | — | — | EP | disclosed |
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-8969550-B2 | Process for the synthesis of cyclic carbamates | LONZA LTD. (CH) | 2015-03-03 | — | — | US | disclosed |
| US-8957204-B2 | Process for the synthesis of cyclic carbamates | LONZA LTD. (CH) | 2015-02-17 | — | — | US | disclosed |
| EP-2627642-B1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA AG (CH) | 2014-12-24 | — | — | EP | disclosed |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | LONZA LTD (CH) | 2013-12-05 | — | — | US | disclosed |
| US-20130217875-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2013-08-22 | — | — | US | disclosed |
| EP-2627642-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | Lonza Ltd (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-20130211077-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2013-08-15 | — | — | US | disclosed |
| EP-2447247-A1 | Process for the synthesis of chiral propargylic alcohols | Lonza Ltd. (CH) | 2012-05-02 | — | — | EP | disclosed |
| EP-2447255-A1 | Process for the synthesis of cyclic carbamates | Lonza Ltd. (CH) | 2012-05-02 | — | — | EP | disclosed |
| WO-2012048886-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | LONZA LTD (CH) | 2012-04-19 | — | — | WO | disclosed |
| EP-2441759-A1 | Process for the synthesis of cyclic carbamates | Lonza Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326101-A1 | Process for the Synthesis of Chiral Propargylic Alcohols | ADH1C, ADH1A, ADH5 | SLC6A2 4018/4885HTR2A 2191/4885HTR2C 2392/4885 |
| US-20130217875-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | PLCG2, PLCG1, CPS1 | SLC6A2 4228/4885HTR2A 3218/4885HTR2C 2073/4885 |
| US-20130324763-A1 | PROCESS FOR THE SYNTHESIS OF CHIRAL PROPARGYLIC ALCOHOLS | ADH1C, ADH1A, ADH5 | SLC6A2 4018/4885HTR2A 2191/4885HTR2C 2392/4885 |
| US-20130211077-A1 | PROCESS FOR THE SYNTHESIS OF CYCLIC CARBAMATES | PLCG2, PLCG1, PLCB1 | SLC6A2 4169/4885HTR2A 3128/4885HTR2C 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.